Johnson & Johnson Proposes $6.5 Billion Settlement in Talcum Powder Cancer Lawsuits

The pharmaceutical giant seeks to resolve nearly all claims through a structured payout over 25 years, pending claimant approval.

Johnson & Johnson offers $6.5 billion to settle allegations that its talc products caused ovarian cancer, aiming to end a long-standing legal battle.
The settlement plan requires approval from 75% of claimants within a three-month voting period, with a potential bankruptcy filing for its subsidiary, LTL Management.
Previous attempts to settle through bankruptcy were rejected by courts, emphasizing the need for claimant consensus in this proposal.
The company maintains that its talc products are safe and do not contain asbestos, despite facing tens of thousands of lawsuits.
If approved, the settlement would prevent future lawsuits and resolve 99.75% of the existing talc-related claims.